Galiximab

Galiximab
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (primate/human)
Target	CD80
Clinical data
ATC code	none;
Identifiers
CAS Number	357613-77-5 ;
ChemSpider	none;
UNII	S9OX9692ZB;
KEGG	D04295 ;
	(what is this?)

Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials.^[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.^[2]

References[]

^ "Biogen Idec: Pipeline". Archived from the original on 2008-05-17. Retrieved 2009-09-24.
^ WHO Drug Information

External links[]

Official website

This monoclonal antibody–related article is a stub. You can help Wikipedia by .

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

[1] "Biogen Idec: Pipeline". Archived from the original on 2008-05-17. Retrieved 2009-09-24.

[2] WHO Drug Information

[1]

[2]